vs
Arcosa, Inc.（ACA）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
Arcosa, Inc.的季度营收约是ICU MEDICAL INC的1.3倍（$716.7M vs $540.7M），Arcosa, Inc.净利率更高（7.3% vs -2.9%，领先10.2%），Arcosa, Inc.同比增速更快（7.6% vs -14.1%），Arcosa, Inc.自由现金流更多（$55.8M vs $36.0M），过去两年Arcosa, Inc.的营收复合增速更高（9.4% vs -2.3%）
Arcosa, Inc.是一家基础设施相关产品及解决方案提供商，业务覆盖建筑、能源、交通三大核心板块，主营公用设施结构件、建筑集料、交通零部件等产品，主要面向北美市场客户，为各类关键基础设施建设项目提供支持。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ACA vs ICUI — 直观对比
营收规模更大
ACA
是对方的1.3倍
$540.7M
营收增速更快
ACA
高出21.7%
-14.1%
净利率更高
ACA
高出10.2%
-2.9%
自由现金流更多
ACA
多$19.8M
$36.0M
两年增速更快
ACA
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $716.7M | $540.7M |
| 净利润 | $52.1M | $-15.7M |
| 毛利率 | 22.9% | 37.5% |
| 营业利润率 | 11.0% | 1.0% |
| 净利率 | 7.3% | -2.9% |
| 营收同比 | 7.6% | -14.1% |
| 净利润同比 | 776.6% | 34.0% |
| 每股收益（稀释后） | $1.06 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACAICUI
| Q4 25 | $716.7M | $540.7M | ||
| Q3 25 | $797.8M | $537.0M | ||
| Q2 25 | $736.9M | $548.9M | ||
| Q1 25 | $632.0M | $604.7M | ||
| Q4 24 | $666.2M | $629.8M | ||
| Q3 24 | $640.4M | $589.1M | ||
| Q2 24 | $664.7M | $596.5M | ||
| Q1 24 | $598.6M | $566.7M |
净利润ACAICUI
| Q4 25 | $52.1M | $-15.7M | ||
| Q3 25 | $73.0M | $-3.4M | ||
| Q2 25 | $59.7M | $35.3M | ||
| Q1 25 | $23.6M | $-15.5M | ||
| Q4 24 | $-7.7M | $-23.8M | ||
| Q3 24 | $16.6M | $-33.0M | ||
| Q2 24 | $45.6M | $-21.4M | ||
| Q1 24 | $39.2M | $-39.5M |
毛利率ACAICUI
| Q4 25 | 22.9% | 37.5% | ||
| Q3 25 | 24.1% | 37.4% | ||
| Q2 25 | 22.5% | 37.9% | ||
| Q1 25 | 19.8% | 34.7% | ||
| Q4 24 | 19.3% | 36.1% | ||
| Q3 24 | 21.3% | 34.8% | ||
| Q2 24 | 20.8% | 34.8% | ||
| Q1 24 | 18.6% | 32.7% |
营业利润率ACAICUI
| Q4 25 | 11.0% | 1.0% | ||
| Q3 25 | 14.1% | 2.6% | ||
| Q2 25 | 12.9% | 1.9% | ||
| Q1 25 | 8.8% | 2.1% | ||
| Q4 24 | 6.5% | 6.0% | ||
| Q3 24 | 5.3% | 1.4% | ||
| Q2 24 | 10.1% | 1.3% | ||
| Q1 24 | 8.9% | -1.9% |
净利率ACAICUI
| Q4 25 | 7.3% | -2.9% | ||
| Q3 25 | 9.2% | -0.6% | ||
| Q2 25 | 8.1% | 6.4% | ||
| Q1 25 | 3.7% | -2.6% | ||
| Q4 24 | -1.2% | -3.8% | ||
| Q3 24 | 2.6% | -5.6% | ||
| Q2 24 | 6.9% | -3.6% | ||
| Q1 24 | 6.5% | -7.0% |
每股收益（稀释后）ACAICUI
| Q4 25 | $1.06 | $-0.63 | ||
| Q3 25 | $1.48 | $-0.14 | ||
| Q2 25 | $1.22 | $1.43 | ||
| Q1 25 | $0.48 | $-0.63 | ||
| Q4 24 | $-0.16 | $-0.97 | ||
| Q3 24 | $0.34 | $-1.35 | ||
| Q2 24 | $0.93 | $-0.88 | ||
| Q1 24 | $0.80 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $214.6M | — |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $2.6B | $2.1B |
| 总资产 | $5.0B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资ACAICUI
| Q4 25 | $214.6M | — | ||
| Q3 25 | $220.0M | — | ||
| Q2 25 | $189.7M | — | ||
| Q1 25 | $167.9M | — | ||
| Q4 24 | $187.3M | $308.6M | ||
| Q3 24 | $756.8M | $312.5M | ||
| Q2 24 | $103.7M | $302.6M | ||
| Q1 24 | $176.5M | $251.4M |
总债务ACAICUI
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $699.9M | — | ||
| Q1 24 | $600.6M | — |
股东权益ACAICUI
| Q4 25 | $2.6B | $2.1B | ||
| Q3 25 | $2.6B | $2.1B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $2.4B | $2.0B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.4B | $2.1B |
总资产ACAICUI
| Q4 25 | $5.0B | $4.1B | ||
| Q3 25 | $5.1B | $4.1B | ||
| Q2 25 | $5.0B | $4.1B | ||
| Q1 25 | $4.9B | $4.2B | ||
| Q4 24 | $4.9B | $4.2B | ||
| Q3 24 | $4.4B | $4.3B | ||
| Q2 24 | $3.8B | $4.3B | ||
| Q1 24 | $3.7B | $4.3B |
负债/权益比ACAICUI
| Q4 25 | 0.57× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.25× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.0M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $36.0M |
| 自由现金流率自由现金流/营收 | 7.8% | 6.6% |
| 资本支出强度资本支出/营收 | 9.0% | 4.6% |
| 现金转化率经营现金流/净利润 | 2.30× | — |
| 过去12个月自由现金流最近4个季度 | $175.5M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ACAICUI
| Q4 25 | $120.0M | $60.6M | ||
| Q3 25 | $160.6M | $56.7M | ||
| Q2 25 | $61.2M | $11.2M | ||
| Q1 25 | $-700.0K | $51.3M | ||
| Q4 24 | $248.2M | $40.2M | ||
| Q3 24 | $135.0M | $36.1M | ||
| Q2 24 | $38.3M | $82.0M | ||
| Q1 24 | $80.5M | $45.8M |
自由现金流ACAICUI
| Q4 25 | $55.8M | $36.0M | ||
| Q3 25 | $121.0M | $27.6M | ||
| Q2 25 | $33.4M | $-8.5M | ||
| Q1 25 | $-34.7M | $36.7M | ||
| Q4 24 | $194.9M | $16.1M | ||
| Q3 24 | $100.6M | $16.2M | ||
| Q2 24 | $-9.3M | $62.5M | ||
| Q1 24 | $26.1M | $29.9M |
自由现金流率ACAICUI
| Q4 25 | 7.8% | 6.6% | ||
| Q3 25 | 15.2% | 5.1% | ||
| Q2 25 | 4.5% | -1.5% | ||
| Q1 25 | -5.5% | 6.1% | ||
| Q4 24 | 29.3% | 2.6% | ||
| Q3 24 | 15.7% | 2.7% | ||
| Q2 24 | -1.4% | 10.5% | ||
| Q1 24 | 4.4% | 5.3% |
资本支出强度ACAICUI
| Q4 25 | 9.0% | 4.6% | ||
| Q3 25 | 5.0% | 5.4% | ||
| Q2 25 | 3.8% | 3.6% | ||
| Q1 25 | 5.4% | 2.4% | ||
| Q4 24 | 8.0% | 3.8% | ||
| Q3 24 | 5.4% | 3.4% | ||
| Q2 24 | 7.2% | 3.3% | ||
| Q1 24 | 9.1% | 2.8% |
现金转化率ACAICUI
| Q4 25 | 2.30× | — | ||
| Q3 25 | 2.20× | — | ||
| Q2 25 | 1.03× | 0.32× | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.13× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 2.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACA
| Engineered Structures | $301.1M | 42% |
| Total Construction Materials | $276.8M | 39% |
| Specialty Materials And Asphalt | $110.2M | 15% |
| Construction Site Support | $28.6M | 4% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
